Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics.

ABSTRACT: Antibody-directed nanotherapeutics (ADNs) represent a promising delivery platform for selective delivery of an encapsulated drug payload to the site of disease that improves the therapeutic index. Although both single-chain Fv (scFv) and Fab antibody fragments have been used for targeting, no platform approach applicable to any target has emerged. scFv can suffer from intrinsic instability, and the Fabs are challenging to use due to native disulfide over-reduction and resulting impurities at the end of the conjugation process. This occurs because of the close proximity of the disulfide bond connecting the heavy and light chain to the free cysteine at the C-terminus, which is commonly used as the conjugation site. Here we show that by engineering an alternative heavy chain-light chain disul

SUBMITTER: Geddie ML 

PROVIDER: S-EPMC9225506 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature